DoJ Prosecutions: USPlabs Guilty, DMBA Firm Indicted From FDA Investigations
USPlabs executives, others plead guilty to felony charges stemming from marketing unsafe products labeled as supplements but containing DMAA and linked to hepatitis. Blackstone Labs and other firms indicted on felony charges following FDA investigation for marketing DMBA-containing products. "It's all very welcome news, but I'm not sure this is going to change the overall environment," says Pieter Cohen, a physician who advocates for tighter regulation of supplement manufacturing and marketing.
You may also be interested in...
"You end up with a recipe for maybe there's adulterants in the product. Maybe the product wasn't manufactured according to the spec, so it's misbranded. Worse, there could be adulterants. In some of those ingredients, there's a lot of potential failures,” says Patrick Runkle, senior litigation counsel at DoJ Consumer Protection Branch, during FDL conference.
Firms moving from noncompliance to compliance with FDA or FTC requirements still could hear from federal prosecutors. “Our office has grown to the point that we generate a fair amount of work ourselves,” says Patrick Runkle, a trial attorney in DoJ Consumer Protection Branch.
James Boccuzzi was the last person sentenced in connection with FDA's investigation of sports supplement firm Blackstone Labs for selling steroid-containing supplements after it ignored agency's warning to stop.